| Abstrakt: |
A new study from the University of Colorado Anschutz Medical Campus focuses on atypical teratoid rhabdoid tumors (ATRT), a highly aggressive pediatric brain tumor characterized by SMARCB1 deletion. The researchers conducted a functional genomic screen and identified BMI1, a component of the Polycomb Repressive Complex 1 (PRC1), as a key target essential for ATRT cell growth. They found that BMI1 cooperates with SMARCB1 deletion to suppress transcription of pro-differentiation pathways and promote self-renewal of tumor stem cells. Inhibition of BMI1 was shown to prolong mice survival and decrease tumor size, suggesting that PRC1/BMI1 inhibition could be a novel therapeutic approach for ATRT. [Extracted from the article] |
